Potassium in the blood is essential to regulate the function of muscles, maintain fluid balance, and control nerve signals. A high potassium diet could lower the risk of heart attack and stroke, reduce high blood pressure, and decrease the threat of osteoarthritis. Ideally, potassium level in the blood should range from 3.6 mmol to 5.2 mmol per liter. However, the level of potassium could surpass the normal level if it is not properly removed from blood due to improper kidney function. This medical condition is known as hyperkalemia, where the potassium level in the blood is higher than normal. The condition can be life threatening if blood potassium level surpasses 6.0 mmol per liter. The most common symptoms of hyperkalemia are tiredness, chest pain, improper heart beating, nausea, and tingling.
The global hyperkalemia drugs market is driven primarily by rise in cases of kidney failure across the world. Additionally, increase in rate of diagnosis and treatment of chronic kidney diseases and hyperkalemia and rise in awareness about these medical conditions are the major factors projected to drive the global hyperkalemia drugs market during the forecast period. However, stringent regulatory guidelines and strict intellectual property right laws are anticipated to restrain the global hyperkalemia drugs market in the near future. Increase in R&D investment by major players and rich pipeline of hyperkalemia drugs are expected to offset these restraints during the forecast period.
In terms of drug type, the global hyperkalemia drugs market can be classified into renin-angiotensin-aldosterone system inhibitors, ace-inhibitors, beta blockers, non-steroidal anti-inflammatory drugs, cyclosporine, heparin, and others. Based on patent, the global hyperkalemia drugs market can be bifurcated into branded and generic. In terms of hyperkalemia type, the global hyperkalemia drugs market can be categorized into chronic hyperkalemia and acute hyperkalemia. Based on distribution channel, the global hyperkalemia drugs market can be divided into hospital pharmacies, retail pharmacies & drugstores, and online sales.
Geographically, the global hyperkalemia drugs market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. A study published in Current Medical Research and Opinion in 2018 indicated that the overall prevalence of hyperkalemia in the U.S. was 1.57%, or 4 million, of the total population in 2014. Moreover, prevalence of hyperkalemia rises with increase in kidney diseases, heart failure, diabetes, and hypertension. North America captured the largest hyperkalemia drugs market share in 2017, due to significant prevalence of hyperkalemia in the U.S., high rate of diagnosis & treatment of the disease in the region, well-established health care infrastructure, and high awareness about hyperkalemia.
An article published by the Clinical Practice Research Datalink in 2017 stated that prevalence of hyperkalemia was high among patients with kidney disease and heart failure. High prevalence of chronic kidney diseases and heart failure, well-established health care infrastructure, and rise in awareness are expected to boost the growth of the hyperkalemia drugs market in Europe during the forecast period. Increase in the geriatric population, rise in cases of hyperkalemia, chronic kidney diseases, heart failure, etc., developing health care infrastructure, and presence of domestic pharmaceutical companies are likely to propel the hyperkalemia drugs market in Asia Pacific in the near future. However, the hyperkalemia drugs market in Latin America and Middle East & Africa is projected to experience sluggish growth during the forecast period due to low health awareness and underdeveloped health care infrastructure.
Key companies in the global hyperkalemia drugs market are AstraZeneca, Relypsa, Inc., Vifor Pharma Management Ltd., Ardelyx, and ZS Pharma, Inc., among others.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.